Trius Therapeutics (TSRX) Posts Narrower than Expected Q4 Loss of 44c/Share

Trius Therapeutics, Inc. (NASDAQ: TSRX) reported Q4 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $3.52 million versus the consensus estimate of $3.82 million.

For earnings history and earnings-related data on Trius Therapeutics, Inc. (TSRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BofA says momentum style supported by earnings revisions
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results